50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
How To Earn a Tax-Advantaged 10% Dividend Yield (Ad)pixel
Judge rejects Justice Dept.'s bid to stop sugar merger
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
One Stock Doubles Your Money, During Crisis? (Ad)
MarketBeat: Week in Review 9/19 – 9/23
China using civilian ships to enhance navy capability, reach
One Stock Doubles Your Money, During Crisis? (Ad)
German leader seeks energy deals, alliances on Gulf trip
World Bank head says he's not a climate denier, won't quit
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
How To Earn a Tax-Advantaged 10% Dividend Yield (Ad)pixel
Judge rejects Justice Dept.'s bid to stop sugar merger
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
One Stock Doubles Your Money, During Crisis? (Ad)
MarketBeat: Week in Review 9/19 – 9/23
China using civilian ships to enhance navy capability, reach
One Stock Doubles Your Money, During Crisis? (Ad)
German leader seeks energy deals, alliances on Gulf trip
World Bank head says he's not a climate denier, won't quit
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
How To Earn a Tax-Advantaged 10% Dividend Yield (Ad)pixel
Judge rejects Justice Dept.'s bid to stop sugar merger
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
One Stock Doubles Your Money, During Crisis? (Ad)
MarketBeat: Week in Review 9/19 – 9/23
China using civilian ships to enhance navy capability, reach
One Stock Doubles Your Money, During Crisis? (Ad)
German leader seeks energy deals, alliances on Gulf trip
World Bank head says he's not a climate denier, won't quit
S&P 500   3,693.23
DOW   29,590.41
QQQ   275.51
Become an Ethical Hacking and Cybercrime Expert
How To Earn a Tax-Advantaged 10% Dividend Yield (Ad)pixel
Judge rejects Justice Dept.'s bid to stop sugar merger
Will Wall Street's Enthusiasm About Datadog Lead To Big Gains?
One Stock Doubles Your Money, During Crisis? (Ad)
MarketBeat: Week in Review 9/19 – 9/23
China using civilian ships to enhance navy capability, reach
One Stock Doubles Your Money, During Crisis? (Ad)
German leader seeks energy deals, alliances on Gulf trip
World Bank head says he's not a climate denier, won't quit
NASDAQ:ANAB

AnaptysBio - ANAB Stock Forecast, Price & News

$25.41
-0.14 (-0.55%)
(As of 09/23/2022 12:00 AM ET)
Add
Compare
Today's Range
$24.57
$25.54
50-Day Range
$20.22
$26.62
52-Week Range
$18.20
$37.89
Volume
253,543 shs
Average Volume
317,330 shs
Market Capitalization
$717.58 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$29.25

AnaptysBio MarketRank™ Forecast

Analyst Rating
Hold
2.40 Rating Score
Upside/​Downside
15.1% Upside
$29.25 Price Target
Short Interest
Bearish
20.80% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.69mentions of AnaptysBio in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.75) to ($3.52) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.41 out of 5 stars

Medical Sector

1030th out of 1,080 stocks

Pharmaceutical Preparations Industry

508th out of 535 stocks

ANAB stock logo

About AnaptysBio (NASDAQ:ANAB) Stock

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

Receive ANAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AnaptysBio and its competitors with MarketBeat's FREE daily newsletter.

ANAB Stock News Headlines

AnaptysBio (NASDAQ:ANAB) Earns "Buy" Rating from HC Wainwright
Analysts Set AnaptysBio, Inc. (NASDAQ:ANAB) Target Price at $32.00
AnaptysBio (NASDAQ:ANAB) Stock Rating Lowered by Truist Financial
See More Headlines
Receive ANAB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for AnaptysBio and its competitors with MarketBeat's FREE daily newsletter.

ANAB Company Calendar

Last Earnings
8/08/2022
Today
9/24/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ANAB
Fax
N/A
Employees
102
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$29.25
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$24.00
Forecasted Upside/Downside
+15.1%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

Net Income
$-57,800,000.00
Net Margins
-448.43%
Pretax Margin
-448.43%

Debt

Sales & Book Value

Annual Sales
$63.17 million
Book Value
$12.89 per share

Miscellaneous

Free Float
18,666,000
Market Cap
$717.58 million
Optionable
Optionable
Beta
0.11

Key Executives

  • Mr. Daniel R. Faga (Age 42)
    Interim Pres & CEO and Director
    Comp: $3.91k
  • Mr. Eric J. LoumeauMr. Eric J. Loumeau (Age 59)
    COO & Gen. Counsel
    Comp: $639.88k
  • Mr. Hamza Suria M.B.A.Mr. Hamza Suria M.B.A. (Age 46)
    M.Sc., Advisory
    Comp: $836.53k
  • Dr. Paul F. Lizzul FAAD (Age 47)
    M.B.A., M.D., M.P.H., Ph.D., Chief Medical Officer
    Comp: $683.17k
  • Mr. Dennis M. Mulroy (Age 67)
    Chief Financial Officer
  • Mr. Benjamin Stone
    Sr. VP of Corp. Devel.
  • Ms. Beth Mueller
    Sr. VP of HR
  • Dr. Martin Dahl Ph.D.
    Sr. VP of Research













ANAB Stock - Frequently Asked Questions

Should I buy or sell AnaptysBio stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AnaptysBio in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ANAB shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ANAB, but not buy additional shares or sell existing shares.
View ANAB analyst ratings
or view top-rated stocks.

What is AnaptysBio's stock price forecast for 2022?

5 analysts have issued 12 month price objectives for AnaptysBio's shares. Their ANAB share price forecasts range from $24.00 to $35.00. On average, they expect the company's share price to reach $29.25 in the next year. This suggests a possible upside of 15.1% from the stock's current price.
View analysts price targets for ANAB
or view top-rated stocks among Wall Street analysts.

How have ANAB shares performed in 2022?

AnaptysBio's stock was trading at $34.75 at the beginning of 2022. Since then, ANAB stock has decreased by 26.9% and is now trading at $25.41.
View the best growth stocks for 2022 here
.

When is AnaptysBio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our ANAB earnings forecast
.

How were AnaptysBio's earnings last quarter?

AnaptysBio, Inc. (NASDAQ:ANAB) issued its quarterly earnings data on Monday, August, 8th. The biotechnology company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($0.95) by $0.20. The biotechnology company earned $1.22 million during the quarter, compared to analysts' expectations of $6.35 million. AnaptysBio had a negative trailing twelve-month return on equity of 31.00% and a negative net margin of 448.43%.

What other stocks do shareholders of AnaptysBio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AnaptysBio investors own include bluebird bio (BLUE), ImmunoGen (IMGN), NVIDIA (NVDA), CRISPR Therapeutics (CRSP), Amarin (AMRN), Editas Medicine (EDIT), Illumina (ILMN), Clovis Oncology (CLVS), Twilio (TWLO) and AbbVie (ABBV).

When did AnaptysBio IPO?

(ANAB) raised $60 million in an initial public offering (IPO) on Thursday, January 26th 2017. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Credit Suisse and Stifel served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is AnaptysBio's stock symbol?

AnaptysBio trades on the NASDAQ under the ticker symbol "ANAB."

Who are AnaptysBio's major shareholders?

AnaptysBio's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Federated Hermes Inc. (8.16%), State Street Corp (4.09%), Woodline Partners LP (3.26%), Point72 Asset Management L.P. (3.02%), Deerfield Management Company L.P. Series C (2.73%) and Assenagon Asset Management S.A. (2.44%). Insiders that own company stock include Ecor1 Capital, Llc, Eric J Loumeau and Hamza Suria.
View institutional ownership trends
.

How do I buy shares of AnaptysBio?

Shares of ANAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is AnaptysBio's stock price today?

One share of ANAB stock can currently be purchased for approximately $25.41.

How much money does AnaptysBio make?

AnaptysBio (NASDAQ:ANAB) has a market capitalization of $717.55 million and generates $63.17 million in revenue each year. The biotechnology company earns $-57,800,000.00 in net income (profit) each year or ($3.88) on an earnings per share basis.

How many employees does AnaptysBio have?

The company employs 102 workers across the globe.

How can I contact AnaptysBio?

AnaptysBio's mailing address is 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.anaptysbio.com. The biotechnology company can be reached via phone at (858) 362-6295 or via email at investors@anaptysbio.com.

This page (NASDAQ:ANAB) was last updated on 9/24/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.